FDA-ready in 12 months by turning complexity into speed. Read the Case Study.
Tustin, CA, USA â September 15, 2025 â Avid Bioservices, Inc., a leading biologics contract development and manufacturing organization (CDMO), today announced the appointment of Kenneth Bilenberg as its new Chief Executive Officer (CEO). A seasoned industry executive with more than 20 years of experience, Bilenberg most recently served as Chief Operating Officer of Fujifilm […]
Read moreSOUTH SAN FRANCISCO, California â August 05, 2025 â Privately held CHO Plus, Inc. announced today a project agreement awarded from the Biomedical Advanced Research and Development Authorityâs (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) for up to $10.4 million for developing high productivity Chinese hamster ovary cell lines for manufacturing filovirus monoclonal antibodies for therapeutic […]
Read moreAvid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners Acquisition of biologics Contract Development and Manufacturing Organisation Avid Bioservices now completed GHO and Ampersandâs deep experience in CDMO investing to support Avidâs next stage of rapid growth including expanded offerings, talent investment and greater geographic reach London, UK, […]
Read moreAvid Bioservices, Inc. Provides Notice of Fundamental Change and Make-Whole Fundamental Change to Holders of its Convertible Notes in Connection with Completed Merger TUSTIN, Calif., February 5, 2025 â Avid Bioservices, Inc. (âAvidâ or the âCompanyâ), a dedicated biologics contract development and manufacturing organization (âCDMOâ) working to improve patient lives by providing high quality development and […]
Read moreTUSTIN, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ: CDMO) (âAvidâ or the âCompanyâ), a dedicated biologics contract development and manufacturing organization (âCDMOâ) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that Avid stockholders voted to approve the transaction with […]
Read moreTUSTIN, Calif. and LONDON and BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ: CDMO) (âAvidâ or the âCompanyâ), a dedicated biologics contract development and manufacturing organization (âCDMOâ) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, GHO Capital Partners LLP (“GHO”) and Ampersand Capital Partners (âAmpersandâ) today announced they have entered into a definitive merger […]
Read more